このアイテムのアクセス数: 86

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
s12985-022-01752-y.pdf1.72 MBAdobe PDF見る/開く
タイトル: Comparison of six antibody assays and two combination assays for COVID-19
著者: Yamamoto, Masaki  kyouindb  KAKEN_id
Okazaki, Kazuyuki
Kitai, Yoko
Shinohara, Koh
Yukawa, Satomi
Noguchi, Taro  KAKEN_id  orcid https://orcid.org/0000-0002-6601-6799 (unconfirmed)
Tanaka, Michio
Matsumura, Yasufumi  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0001-8595-8944 (unconfirmed)
Nishiyama, Yukiko
Nagao, Miki  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-8886-6145 (unconfirmed)
著者名の別形: 山本, 正樹
岡崎, 一幸
北井, 陽子
篠原, 浩
湯川, 理己
野口, 太郎
田中, 美智男
松村, 康史
西山, 有紀子
長尾, 美紀
キーワード: COVID-19
SARS-CoV-2
Antibody testing
Serology
発行日: 2022
出版者: Springer Nature
BMC
誌名: Virology Journal
巻: 19
論文番号: 24
抄録: [Introduction] In this work, six SARS-CoV-2-specific antibody assays were evaluated, namely, two pan-immunoglobulin (pan-Ig) assays [Roche Elecsys Anti-SARS-CoV-2 (named "Elecsys" in this study) and the PerkinElmer SuperFlex™ Anti-SARS-CoV-2 Ab Assay (SuperFlex_Ab)], two IgM assays [SuperFlex™ Anti-SARS-CoV-2 IgM Assay (SuperFlex_IgM) and YHLO iFlash-SARS-CoV-2 IgM (iFlash_IgM)], and two IgG assays [SuperFlex™ Anti-SARS-CoV-2 IgG Assay (SuperFlex_IgG) and iFlash-SARS-CoV-2 IgG (iFlash_IgG)]. Combination assays of SuperFlex™ (SuperFlex_any) and iFlash (iFlash_any) were also evaluated. [Methods] A total of 438 residual serum samples from 54 COVID-19 patients in the COVID-19 group and 100 samples from individuals without evidence of SARS-CoV-2 infection in the negative control group were evaluated. [Results] In the early stage of COVID-19 infection, within 14 days of symptom onset, the seropositive rate was lower than that of the late stage 15 days after onset (65.4% vs 99.6%). In the total period, the pan-Ig and IgG assays had higher sensitivity (90.8–95.3%) than the IgM assays (36.5–40.7%). SuperFlex_Ab and SuperFlex_any had higher sensitivity than Elecsys and SuperFlex_IgG (p < 0.05). The specificity of all the assays was 100%, except for SuperFlex_IgM (99.0%). The concordance rate between each assay was higher (96.4–100%) in the late stage than in the early stage (77.4–98.1%). [Conclusion] For the purpose of COVID-19 diagnosis, antibody testing should be performed 15 days after onset. For the purpose of epidemiological surveillance, highly sensitive assays should be used as much as possible, such as SuperFlex_Ab, iFlash_IgG and their combination. IgM assays were not suitable for these purposes.
著作権等: © The Author(s) 2022.
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
URI: http://hdl.handle.net/2433/278467
DOI(出版社版): 10.1186/s12985-022-01752-y
PubMed ID: 35115008
出現コレクション:学術雑誌掲載論文等

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス Creative Commons